Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94.
View in:
PubMed
subject areas
Administration, Oral
Administration, Oral
Adult
Adult
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Agents
Antineoplastic Agents
Biomarkers, Tumor
Biomarkers, Tumor
Disease-Free Survival
Disease-Free Survival
Endometrial Neoplasms
Endometrial Neoplasms
ErbB Receptors
ErbB Receptors
Female
Female
Humans
Humans
Ki-67 Antigen
Ki-67 Antigen
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Protein Kinase Inhibitors
Protein Kinase Inhibitors
Quinazolines
Quinazolines
Receptors, Estrogen
Receptors, Estrogen
Receptors, Progesterone
Receptors, Progesterone
Signal Transduction
Signal Transduction
Survival Rate
Survival Rate
authors with profiles
Robert S Mannel